Risk of relapses during pregnancy among multiple sclerosis patients

Affiliations

01 September 2019

-

doi: 10.1016/j.msard.2019.06.007


Abstract

Background: Relapse rate in women with Multiple Sclerosis (MS) is reduced during pregnancy especially in the third trimester according to the previous studies.

Objectives: To measure the annual relapse rate (ARR) in women with MS during pregnancy.

Methods: A retrospective study was conducted using prospectively collected data from two MS registries in Kuwait and Lebanon. Demographics, clinical characteristics including relapses, disease modifying therapies (DMTs) and their washout periods were extracted. The annual relapse rates pre and post pregnancies were compared and the relationship between relapses and prior use of different DMTs was assessed.

Results: Data of 164 pregnancies (132 MS patients) was reviewed. Mean age and disease duration at the time of pregnancy confirmation were 32.4 ± 5.3 and 7.8 ± 4.7 years respectively. Most patients (91.7%; n = 121) were on DMTs in the year prior to pregnancy. The pre-pregnancy ARR was 0.10 (95% CI: 0.04 - 0.13), which increased to 0.20 (95% CI: 0.13- 0.29) during pregnancy. Most relapses occurred either during the 1st (ARR = 0.24; 95% CI: 0.12 - 0.44) or 3rd (ARR = 0.32; 95%CI: 0.17 - 0.53) trimesters. Fingolimod (31.8%) and natalizumab (22.7%) were the most commonly prescribed DMTs in patients who sustained relapses during pregnancy. The mean washout period was significantly longer among subjects with relapses (9.3 ± 6.6 vs. 2.5 ± 3.9; p < 0.001) than those of without relapses.

Conclusions: Relapse rate during pregnancy was higher than previous studies conducted in patients on platform therapies or untreated. Longer washout period prior to conception was associated with increased relapses especially in fingolimod and natalizumab treated patients.

Keywords: Disease modifying therapy; Middle East; Multiple sclerosis; Pregnancy; Relapse.


Similar articles

Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.

Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J.Neurology. 2018 Mar 6;90(10):e840-e846. doi: 10.1212/WNL.0000000000005065. Epub 2018 Feb 2.PMID: 29429970

Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.

Berenguer-Ruiz L, Gimenez-Martinez J, Palazón-Bru A, Sempere AP.J Neurol. 2019 Oct;266(10):2512-2517. doi: 10.1007/s00415-019-09450-6. Epub 2019 Jun 29.PMID: 31256279

Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.

Villaverde-González R, Candeliere-Merlicco A, Alonso-Frías MA, Aparicio Castro E, Carrillo Alcaraz A, Mallada Frechín J, Pérez Sempere Á.Mult Scler Relat Disord. 2020 Nov;46:102518. doi: 10.1016/j.msard.2020.102518. Epub 2020 Sep 16.PMID: 32977075

[Multiple sclerosis and pregnancy].

Vukusic S, Confavreux C.Rev Neurol (Paris). 2006 Mar;162(3):299-309. doi: 10.1016/s0035-3787(06)75016-0.PMID: 16585885 Review. French.

The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS).

Alwan S, Chambers CD, Armenti VT, Sadovnick AD.Mult Scler Relat Disord. 2015 Jan;4(1):6-17. doi: 10.1016/j.msard.2014.10.001. Epub 2014 Oct 24.PMID: 25787048 Review.


Cited by

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis.

Menascu S, Siegel-Kirshenbaum M, Dreyer-Alster S, Warszawer Y, Magalashvili D, Dolev M, Mandel M, Harari G, Achiron A.Mult Scler J Exp Transl Clin. 2023 Jan 17;9(1):20552173221151127. doi: 10.1177/20552173221151127. eCollection 2023 Jan-Mar.PMID: 36687367 Free PMC article.

Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.

Villaverde-González R.Degener Neurol Neuromuscul Dis. 2022 Jan 5;12:1-21. doi: 10.2147/DNND.S203406. eCollection 2022.PMID: 35023987 Free PMC article. Review.

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.

Hellwig K, Verdun di Cantogno E, Sabidó M.Ther Adv Neurol Disord. 2021 Nov 12;14:17562864211051012. doi: 10.1177/17562864211051012. eCollection 2021.PMID: 34876925 Free PMC article. Review.

What Can We Learn from Sex Differences in MS?

Coyle PK.J Pers Med. 2021 Oct 7;11(10):1006. doi: 10.3390/jpm11101006.PMID: 34683148 Free PMC article.

Early Aggressive Treatment Approaches for Multiple Sclerosis.

Simpson A, Mowry EM, Newsome SD.Curr Treat Options Neurol. 2021;23(7):19. doi: 10.1007/s11940-021-00677-1. Epub 2021 May 15.PMID: 34025110 Free PMC article. Review.


KMEL References